GT Biopharma Shows NK Combination Data

Preclinical results at SITC 2026 link its B7-H3 tri-specific NK cell engager with a KRAS inhibitor in pancreatic cancer models.

Updated on Nov. 9, 2026 in Biotech

Laboratory bench with clear glass petri dishes, plain test tubes, and a cell-culture flask holding pink liquid under cool clinical light.
GT Biopharma reported preclinical data at the SITC 2026 meeting in Phoenix showing its GTB-5550 NK cell engager with a KRAS inhibitor produced complete tumor clearance in several animals. AI Illustration. Upload story photo >

GT Biopharma presented preclinical data at the SITC 2026 Annual Meeting in Phoenix, Arizona, showing that its GTB-5550 tri-specific NK cell engager combined with a KRAS inhibitor promoted NK cell infiltration and produced complete tumor clearance in several animals. The company announced the data in a press release on November 9, 2026.

Why it matters

Monotherapy with RAS inhibitors can trigger early resistance through bypass pathways, and the combination approach is designed to sensitize pancreatic tumor cells to NK cell cytotoxicity. The company is considering a future Phase 1b study to evaluate the pairing in patients.

The results come from orthotopic xenograft models, showing a two-fold increase in tumor infiltration compared with KRAS inhibitor alone. Human efficacy and safety of the combination remain untested, and a Phase 1a/1b basket trial of GTB-5550 monotherapy, including a pancreatic cancer cohort, is still ongoing.

The players

GT Biopharma

A clinical-stage biopharmaceutical company developing immunotherapies, headquartered in San Francisco, California, that is advancing the GTB-5550 tri-specific NK cell engager.

University of Minnesota

A public research university whose researchers developed the TriKE technology that GT Biopharma has licensed for its NK cell engager platform.

The details

GTB-5550 is a B7-H3-targeted tri-specific NK cell engager, and in preclinical models its combination with a KRAS inhibitor reduced local invasion and prevented metastasis in pancreatic cancer xenografts. The presentation was given as an oral abstract by Paarth Dodhiawala on November 6, 2026.

Timeline

  1. November 4-8, 2026: SITC 2026 Annual Meeting in Phoenix, Arizona

  2. November 6, 2026: Oral presentation of abstract 655

  3. November 9, 2026: GT Biopharma announces the preclinical data by press release

The Tech Race

The work extends the TriKE platform from its origins at the University of Minnesota toward combination therapy, addressing the early resistance that limits RAS inhibitors used alone. It positions GT Biopharma among companies racing to pair NK cell engagers with targeted oncology drugs in hard-to-treat cancers such as pancreatic cancer.

For patients and caregivers tracking pancreatic cancer options, this remains preclinical research with no change to available treatment today. Anyone interested in the GTB-5550 basket trial can look for enrollment details on ClinicalTrials.gov under identifier NCT07541573.

The takeaway

Combination strategies that pair immune-cell therapies with targeted drugs are being tested to overcome resistance, but preclinical success does not yet predict clinical outcomes. Readers should watch for human trial results before drawing conclusions about efficacy.

Further reading

Explore more Biotech coverage on how cell therapies are being combined with targeted drugs.